Thea M. Friedman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thea M. Friedman has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Robert Korngold
Cancer Center, Hackensack University Medical Center, NJ
2 shared publicationsChristine G. DiRienzo
Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
1 shared publicationGeorge F. Murphy
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
1 shared publicationJenny Zilberberg
Cancer Center, Hackensack University Medical Center, NJ
1 shared publicationJoanne Filicko-O'HAra
Hematologic Malignancies, Blood and Marrow Transplant Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
1 shared publicationKira Goldgirsh
Cancer Center, Hackensack University Medical Center, NJ
1 shared publication
Latest Publications
- 15 October 2008
- Published by American Society of Hematology in Blood
- Vol. 112 (8) , 3517-3525
Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vβ use: a new paradigm for designer allogeneic blood and marrow transplantation
Following allogeneic blood and marrow transplantation (BMT), mature donor T cells can enhance engraftment, counteract opportunistic infections, and mount graft-versus-tumor (GVT) responses, but at the risk of developing graft-versus-host disease (GVHD). With the aim of separating the beneficial effects of donor T cells from GVHD, one approach would be to selectively deplete subsets of alloreactive T cells in the hematopoietic cell inoculum. In this regard, TCR Vβ repertoire analysis by CDR3-size spectratyping can be a powerful tool for the characterization of alloreactive T-cell responses. We investigated the potential of this spectratype approach by comparing the donor T-cell alloresponses generated in vitro against patient peripheral blood lymphocytes (PBLs) with those detected in vivo posttransplantation. The results indicated that for most Vβ families that exhibited alloreactive CDR3-size skewing, there was a robust overlap between the in vitro antipatient and in vivo spectratype histograms. Thus, in vitro spectratype analysis may be useful for determining the alloreactive T-cell response involved in GVHD development and, thereby, could serve to guide select Vβ family depletion for designer transplants to improve outcomes.
- 15 October 2008
- Published by American Society of Hematology in Blood
- Vol. 112 (8) , 3517-3525
Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vβ use: a new paradigm for designer allogeneic blood and marrow transplantation
Following allogeneic blood and marrow transplantation (BMT), mature donor T cells can enhance engraftment, counteract opportunistic infections, and mount graft-versus-tumor (GVT) responses, but at the risk of developing graft-versus-host disease (GVHD). With the aim of separating the beneficial effects of donor T cells from GVHD, one approach would be to selectively deplete subsets of alloreactive T cells in the hematopoietic cell inoculum. In this regard, TCR Vβ repertoire analysis by CDR3-size spectratyping can be a powerful tool for the characterization of alloreactive T-cell responses. We investigated the potential of this spectratype approach by comparing the donor T-cell alloresponses generated in vitro against patient peripheral blood lymphocytes (PBLs) with those detected in vivo posttransplantation. The results indicated that for most Vβ families that exhibited alloreactive CDR3-size skewing, there was a robust overlap between the in vitro antipatient and in vivo spectratype histograms. Thus, in vitro spectratype analysis may be useful for determining the alloreactive T-cell response involved in GVHD development and, thereby, could serve to guide select Vβ family depletion for designer transplants to improve outcomes.
- Open Access
- 1 August 2006
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 12 (8) , 818-827
T-Cell Receptor Vα Spectratype Analysis of a CD4-Mediated T-Cell Response against Minor Histocompatibility Antigens Involved in Severe Graft-versus-Host Disease
- 1 August 2006
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 12 (8) , 818-827
Open AccessT-Cell Receptor Vα Spectratype Analysis of a CD4-Mediated T-Cell Response against Minor Histocompatibility Antigens Involved in Severe Graft-versus-Host Disease